Glucagon-like peptide-1 receptor agonists such as Ozempic, originally developed for diabetes management and later approved for weight loss, are being studied for their potential to address age-related diseases, The Wall Street Journal reported March 10…
Blockbuster GLP-1 medications like Ozempic and Wegovy are transforming patient care, altering surgery volumes and redefining the healthcare industry’s financial landscape.
An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company’s expectations of 25% weight loss.
As patients scramble for Ozempic and other blockbuster GLP-1 medications, the FDA has set a deadline for compounded versions and health plans are continuing to further restrict coverage.
Commercial insurance coverage of blockbuster GLP-1 drugs has not expanded much over the past year, despite growing demand and expanded indications, according to a new report from GoodRx.
Six months after Eli Lilly began selling discounted vials of its blockbuster weight loss drug Zepbound, the company expanded the offering Feb. 25 to include cheaper, high-dose Zepbound vials.
Compounding pharmacies and telehealth companies selling lower-cost versions of Novo Nordisk’s Ozempic and Wegovy will soon have to halt production after the FDA set deadlines to phase out compounded semaglutide.
A new analysis of data from the phase 3 STEP (semaglutide treatment effect in people with obesity) trials shows that adults using Wegovy for obesity treatment were more likely to discontinue or reduce the intensity of their antihypertensive and lipid-l…
Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type 2 diabetes and weight loss.
As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
